tax in Medical Technology

NYC Department of Health's 'Get Some NYC Condoms' Sends Wrong Message and Misuses Tax Dollars, says MIM President Bob Peters

NEW YORK, Feb. 20 /PRNewswire/ -- On February 13, the NYC Department of Health "unveiled a brand new look for the NYC Condom and launched a cutting- edge media campaign to encourage New Yorker's to 'get some.'" The Release said further that "street teams" would hand out free condoms at "busy c...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...e (Loss) from Continuing Operations, Net of Income tax Benefit Net loss from continuing operations ... Accounting rules require Isis to record an income tax benefit of $656,000 on a line called "Income tax Benefit" as part of its financial results from con...

Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study

... affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators and tax obligations and risks; the impact of temporarily suspending U.S. distribution of one of our key hip replacement products; product liability and intell...

New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform

...ry important. Forty-six percent rated prevention as a 10 out of 10. Overall, prevention was rated higher than all other proposals, including providing tax credits to small businesses and prohibiting health insurers from denying coverage based on health status. "This survey underscores what I have b...

Spherix Reports First Quarter 2009 Earnings

... ------ ------- Loss before taxes (2,066,084) (1,914,234) Income tax expense - - --- --- Net loss ...

Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders

...or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. The designation provides the drug developer with tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance, waiver of Prescription ...

Roundtable Calls President's Embryonic Stem Cell Decision: Bankrupt

...s frozen in failure all over the world while autologous stem cells are providing real cures without the problems of immune system rejections. Throwing tax dollars into embryonic stem cell research is a monumental waste of resources. It is unfortunate for taxpayers that President Obama has chosen to...

Cancer Research 'David' Hopes to Slay 'Cancer Goliath'

...their goal for the eradication of cancer." A Preliminary Patent Application has been filed through Sonnenschein Nath & Rosenthal. A tax Deductable Donation can be sent to P.O. Box 30603 Phoenix, Arizona 85046. For further information, you can contact Eroca Daniel at CHAI Founda...

Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmer's Trabecular Metal(TM) Technology

... affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators and tax obligations and risks; the impact of temporarily suspending U.S. distribution of one of our key hip replacement products; product liability and intell...

EntreMed Presents Initial Clinical Results for ENMD-2076

...rapy developed to treat diseases that affect fewer than 200,000 persons in the United States. Sponsors of drugs granted orphan designation qualify for tax credit and marketing exclusivity incentives of the Orphan Drug Act. EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M...

Franco Nuschese Tapped by Robert C. Gallo Foundation for AIDS and Virus Research

...ct millions around the globe. The Robert C. Gallo Foundation is a 501c(3) not-for-profit foundation established to eradicate HIV/AIDS. All gifts are tax deductible. www.gallofoundation.org Contact: Richard Jacobs 410-706-4616 rsjacobs@gallofoundation.org ...

Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults

...ssionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and maj...

2008 Human Research Protection Award Recipients Announced

...eview, compliance, legal, and consulting organizations. About Health Improvement Institute : Health Improvement Institute is a non-profit, tax exempt, 501(c)3, charitable organization dedicated to improving the quality and productivity of America's health care. The Institute's principal progr...

Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent

...cts, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our Annual Report on Form 10-K f...

Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA

...ases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the US after product approval. About Reviroc(TM) R...

Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey

...nt. Orphan drug designation provides U.S. marketing exclusivity for seven years if marketing approval is received from the FDA, in addition to certain tax benefits for qualifying expenses. About the AIMM Trial Vical is conducting a Phase 3 pivotal trial of the company's Allovectin-7(R) ca...

Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040

...y for the drug upon FDA approval, as well as the opportunity to apply for funding from the U.S. government to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential waiver of the FDA's application user fee. About Hypophosphatasia Hypophosphatasia is a rare, ...

Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351

...to treatments for diseases that affect fewer than 200,000 people in the United States and provides the benefits of market exclusivity for seven years, tax credits, and a waiver of FDA user fees. "The decision by FDA to grant CPX-351 orphan drug designation reinforces the importance of developing novel ...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

... (86) - (149) - (454) Other expense - - - - (1,180) Loss before tax benefit (9,396) (9,219) (19,091) (16,874) (142,404) (Provision for)/ benefit from income taxes - (75) -...

Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial

...nt. Orphan drug designation provides U.S. marketing exclusivity for seven years if marketing approval is received from the FDA, in addition to certain tax benefits for qualifying expenses. About Metastatic Melanoma The American Cancer Society has estimated that more than 62,000 new diagnoses of, and ...

Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension

...r period. In addition to potential market exclusivity, orphan drug designation provides protocol assistance, advice on the conduct of clinical trials, tax credits for clinical research expenses, grant funding for research of rare disease treatments and waiver of the Prescription Drug User Fee Act filing ...

DATATRAK International Reports First Quarter Results for 2008

...y & equipment, net 3,214,069 3,534,799 Deferred tax assets 1,301,700 1,399,000 Intangible ass... before income taxes (2,232,885) (1,868,927) Income tax expense - 26,300 Net loss ...

Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results

... Investment and other income, net 939 1,978 Loss before income taxes (20,861) (11,680) Income tax benefit 401 111 Net loss $(20,460) $(11,569) Basic and diluted...

Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report

...nt. Orphan drug designation provides U.S. marketing exclusivity for seven years if marketing approval is received from the FDA, in addition to certain tax benefits for qualifying expenses. Patients featured in the video report were selected from complete responders in earlier trials, and do not represe...

Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks

...owth; use and protection of intellectual property; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations. The ...

Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec

...ment, use and protection of intellectual property; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations. Th...

Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights

... 139 431 836 1,454 Net loss before income tax benefit (3,218) (18,233) (24,790) (57,710) Income tax benefit 1,470 929 1,470 929 Net loss ...

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

... ---------- ---------- ---------- ---------- Loss before income taxes (9,556) (15,323) (35,282) (31,695) Income tax (benefit) expense - (396) 3 (388) ---------- ---------- ---------- ---...

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

...and Merck. Operational subsidies from the research tax credit, which are deducted from research and devel... increase completed in February 2007. The income tax expense incurred by NicOx in 2007 relates principa...ial year, the significant increase in the research tax credit and its impact on the research and developm...

CEL-SCI Corporation Reports First Quarter Financial Results

... INTEREST EXPENSE (144,016) (347,246) NET LOSS BEFORE INCOME TAXES (1,842,735) (1,112,359) INCOME tax PROVISION - - NET LOSS (1,842,735) (1,112,359) DIVIDENDS ...

Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia

...n Drug Designation allows special incentives for sponsors planning to test a product for use in a rare disease or condition. These incentives include, tax credits, research and development grant funding, and reduced filing fees at the time of application for marketing approval. Once approved, the product...

Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis

...ain key manufacturing and supply sources (including sole supplier and plant manufacturing sources); (5) the ability to successfully manage regulatory, tax and legal matters (including product liability, patent, and intellectual property matters as well as those related to the integration of Gillette and ...

Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa

...to receive marketing approval for this type of therapeutic drug product. In addition, the designation would allow Fovea to apply for research funding, tax credits for certain research expenses, and protocol assistance. Similar orphan drug designation is currently being assessed in the USA by the Food and...

Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate

...es. Drug products that receive orphan drug designation obtain seven years of marketing exclusivity from the date of FDA marketing approval, as well as tax credits for clinical trial costs and waivers of marketing application filing fees. About Jazz Pharmaceuticals, Inc. Jazz Pharmaceuticals, Inc. is ...

Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

...ven years of market exclusivity. Additionally, the sponsor of the product is offered incentives which include eligibility for research grants, certain tax benefits, protocol assistance and possible exemptions or reductions of certain regulatory fees during development or at a time of market approval. A...

Alfacell Reports Financial Results for First Quarter of Fiscal 2008

...rom operations (2,787,307) (2,496,223) Interest income, net 60,507 123,287 State tax benefit - - Net loss $(2,726,800) $(2,372,936) Net los...

Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme

...ven years of market exclusivity. Additionally, the sponsor of the product is offered incentives which include eligibility for research grants, certain tax benefits, protocol assistance and possible exemptions or reductions of certain regulatory fees during development or at a time of market approval. A...

Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin

...ucts and our ability to obtain or meet the closing conditions in the merger agreement with Somanta Pharmaceuticals, Inc. and applicable regulatory and tax requirements, and to otherwise complete the merger in a timely manner, yet there can be no assurances that the closing conditions will be met or waive...

Vanda Pharmaceuticals Reports Third Quarter 2007 Results

... 1,586,053 683,073 4,679,488 1,681,534 Loss before tax provision (21,935,841) (12,124,161) (53,311,214) (51,619,693) Income tax provision 7,660 - 10,070 - ...

The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy

...ic efforts with the goal to increase sales and return to profitability. No tax provision or benefits, to reduce losses, are provided for the quarter and n...posed by the federal alternative minimum taxes or for compliance with state tax regulations, since the Company is in a net operating loss carry-forward pos...